Literature DB >> 6247966

Comparative in vitro activity of 1-oxa-beta-lactam (LY127935) and cefoperazone with other beta-lactam antibiotics against anaerobic bacteria.

M V Borobio, J Aznar, R Jimenez, F Garcia, E J Perea.   

Abstract

The in vitro activity of 1-oxa-beta-lactam (LY127935), cefoperazone (T-1551), cefuroxime, cefsulodin, cefaclor, cefotaxime, and cefoxitin on 85 anaerobic clinical isolates (30 Bacteroides, 30 Clostridium, 25 Peptococcaceae) was simultaneously determined by the agar dilution test in two different media, Brucella Agar (Difco Laboratories) and Wilkins-Chalgren agar. In Wilkins-Chalgren agar, 90% of Bacteroides were inhibited by (micrograms per milliliter): LY127935, 0.5; T-1551, 64; cefoxitin or cefuroxime, 8; cefsulodin or cefotaxime, 32; and cefaclor, 128. All Clostridia were inhibited in Wilkins-Chalgren by (micrograms per milliliter): LY127935, 4; T-1551, 2; cefoxitin, 6; cefuroxime, 0.12; cefsulodin, 0.5; cefaclor, 1; and cefotaxime, 8. All Peptococccaceae were inhibited by T-1551, cefsulodin or cefotaxime at 4 microgram/ml and by cefoxitin or cefuroxime at 1 to 2 microgram/ml. With cefaclor at 8 microgram/ml, 92% of strains were inhibited, and LY127935 at 16 microgram/ml only inhibited 64% of strains. LY127935 was the most active of the antibiotics tested against Bacteroides, showing good activity against Clostridia and poor activity on Peptococcaceae, whereas T-1551 was more active against Peptococccaceae and had similar activity against Clostridia and poor activity on Bacteroides. There are no significant differences between minimal inhibitory concentrations obtained in Brucella Agar and those obtained in Wilkins-Chalgren.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6247966      PMCID: PMC283746          DOI: 10.1128/AAC.17.2.129

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Medium for use in antibiotic susceptibility testing of anaerobic bacteria.

Authors:  T D Wilkins; S Chalgren
Journal:  Antimicrob Agents Chemother       Date:  1976-12       Impact factor: 5.191

2.  Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

3.  Cefoxitin sodium activity against anaerobes: effect of the inoculum size, pH variation and different culture media.

Authors:  E J Perea; J Aznar; M C Garcia-Iglesias; M V Borobio
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

4.  Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro.

Authors:  J M Hamilton-Miller; W Brumfitt; A V Reynolds
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

5.  Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolates.

Authors:  R N Jones; P C Fuchs; T L Gavan; E H Gerlach; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1977-07       Impact factor: 5.191

6.  Comparative in vitro activity of newer cephalosporins against anaerobic bacteria.

Authors:  A W Chow; D Bednorz
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

7.  In vitro activity of cefaclor against aerobic and anaerobic bacteria.

Authors:  V T Bach; M M Khurana; H Thadepalli
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

8.  Susceptibility of anaerobic bacteria to 23 antimicrobial agents.

Authors:  V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

9.  HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.

Authors:  H C Neu; N Aswapokee; P Aswapokee; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

10.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

  10 in total
  23 in total

1.  Effect of pancreatitis on moxalactam excretion in pancreatic fluids of dogs and man.

Authors:  E Rubinstein; D Meissel; E Klein; Y Samra; R Schwartzkopf; G Ben-Ari
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

2.  Comparative in vitro activity of ceftriaxone against anaerobic bacteria.

Authors:  R D Rolfe; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

3.  Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.

Authors:  T O Kurtz; D J Winston; J A Hindler; L S Young; W L Hewitt; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

4.  Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.

Authors:  W E Owens; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

5.  Factors affecting the in vitro activity of cefoperazone against the Bacteroides fragilis group.

Authors:  V L Sutter; Y Y Kwok
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

6.  Moxalactam therapy of serious infections.

Authors:  P Van der Auwera; N Clumeck; Y Van Laethem; R Vanhoof; J P Butzler
Journal:  Infection       Date:  1983 Jul-Aug       Impact factor: 3.553

7.  Comparative activities of 13 beta-lactam antibiotics.

Authors:  H L Muytjens; J van der Ros-van de Repe
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

8.  Comparative in vitro activities of cefpiramide and apalcillin against anaerobic bacteria.

Authors:  H Wexler; W T Carter; B Harris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

9.  Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.

Authors:  C J Schleupner; J C Engle
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

10.  In vitro activity of cefoperazone against nonfermenters and Aeromonas hydrophila.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.